Plus   Neg

Avista Corp. Confirms Earnings Guidance - Quick Facts

Avista Corp. (AVA) confirmed its 2020 earnings guidance to a consolidated range of $1.75 to $1.95 per share. The company expects to be near the midpoint of the guidance range. Analysts polled by Thomson Reuters expect the company to report profit per share of $1.86. Analysts' estimates typically exclude special items.

Third quarter net income to shareholders was $4.9 million, or $0.07 per share, compared to $5.1 million, or $0.08 per share, a year ago. On average, five analysts polled by Thomson Reuters expected the company to report profit per share of $0.12, for the quarter.

Third quarter operating revenues declined to $263.56 million from $274.93 million, previous year. Analysts expected revenue of $301.1 million, for the quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration granted emergency use authorization (EUA) for the first and only clinical T cell-based test for patients to detect the unique T-cell signature specific to SARS-CoV-2, the virus that causes COVID-19. The test confirms recent or prior COVID-19 infection. Developed by Adaptive Biotechnologies, T-Detect COVID Test is a next generation sequencing based (NGS) test. AstraZeneca's one batch of Covid vaccine has been suspended by Austrian health authorities following reports of a death and an illness after receiving vaccination, reports said. The issues were reported in the district clinic of Zwettl in Lower Austria province. The Federal Office for Safety in Health Care in the country said the remaining stocks of the affected AstraZeneca/Oxford Covid-19 vaccine DuPont (DD) announced Monday that it has agreed to acquire Laird Performance Materials from with private equity firm Advent International for $2.3 billion. The company will use existing cash balances for the acquisition. The transaction is expected to close in the third quarter of 2021, subject to regulatory...
Follow RTT